Roche’s Perettie to head cell therapy at Kite
Plus: Ochre appoints Forster as chairperson and updates from Women In Bio, Verismo and MIG
Cindy Perettie will oversee the cell therapy business of Kite Pharma, a Gilead Sciences Inc. (NASDAQ:GILD) company, starting May 30. Perettie, who will be EVP and become a member of Gilead’s senior leadership team, was most recently head of molecular lab solutions at Roche (SIX:ROG; OTCQX:RHHBY).
Ochre Bio Ltd. appointed Eliot Forster as chairperson. Forster was CEO of F-star Therapeutics Inc. (NASDAQ:FSTX) and Immunocore Holdings plc (NASDAQ:IMCR), and chairperson of Avacta Group plc (LSE:AVCT). Ochre is developing RNA-based medicines to treat chronic liver disease...